Imiglucerase biosimilar - Dong-A ST

Drug Profile

Imiglucerase biosimilar - Dong-A ST

Alternative Names: DA 3811; Glucosylceramidase analogue - Dong-A Pharmaceutical; β-glucoerebrosidase analogue - Dong-A Pharmaceutical

Latest Information Update: 20 May 2015

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Enzymes; Glucosidases; Peptidomimetics
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Gaucher's disease

Highest Development Phases

  • Phase I Gaucher's disease

Most Recent Events

  • 27 Oct 2013 Biomarkers information updated
  • 30 Sep 2013 Phase-I clinical trials in Gaucher's disease in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top